Difference between revisions of "Lepirudin (Refludan)"
m |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
||
| Line 25: | Line 25: | ||
[[Category:Venous thromboembolism (VTE) medications]] | [[Category:Venous thromboembolism (VTE) medications]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1998]] |
[[Category:Discontinued]] | [[Category:Discontinued]] | ||
Revision as of 19:24, 30 July 2018
Discontinued by manufacturer in 2012
General information
Class/mechanism: Direct thrombin inhibitor, binds to thrombin and inhibits its effects of catalyzing the formation of fibrin from fibrinogen, platelet aggregation, activation of protein C, and activation of coagulation factors V, VIII, and XIII.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
Also known as
- Brand name: Refludan